BIRMINGHAM, Ala., Sept. 8 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today announced that executives plan to provide corporate summaries at two upcoming investor conferences.
Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, is scheduled to present a corporate summary at the NewsMarkers in the Biotech Industry investment conference hosted by BioCentury and ThomsonReuters in New York on Wednesday, September 16, 2009 at 2:00 p.m. Eastern Time.
BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. BioCryst has discovered and progressed two novel compounds into late-stage pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. The Company’s strategic partnerships with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings Limited validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company’s Web site at www.biocryst.com.
BCRXW
BioCryst Pharmaceuticals, Inc.
